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Medical School, Singapore
Many patients with pernicious anemia are treated with lifelong intramuscular (IM) vitamin 
B12 replacement. As early as the 1950s, there were studies suggesting that oral vitamin 
B12 replacement may provide adequate absorption. Nevertheless, oral vitamin B12 
replacement in patients with pernicious anemia remains uncommon in clinical practice. 
The objective of this review is to provide an update on the effectiveness of oral vitamin 
B12 for the treatment of pernicious anemia, the recommended dosage, and the required 
frequency of laboratory test and clinical monitoring. Relevant articles were identified by 
PubMed search from January 1, 1980 to March 31, 2016 and through hand search of 
relevant reference articles. Two randomized controlled trials, three prospective papers, 
one systematic review, and three clinical reviews fulfilled our inclusion criteria. We found 
that oral vitamin B12 replacement at 1000 μg daily was adequate to replace vitamin B12 
levels in patients with pernicious anemia. We conclude that oral vitamin B12 is an effec-
tive alternative to vitamin B12 IM injections. Patients should be offered this alternative 
after an informed discussion on the advantages and disadvantages of both treatment 
options.
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iNTRODUCTiON
Vitamin B12 deficiency is a common condition, and many are undiagnosed. Absolute deficiency 
occur up to 6% of those aged 60 years and older, whereas marginal deficiency occur in close to 20% of 
patients in later life (1). The manifestation of Vitamin B12 deficiency ranges from subtle, non-specific 
clinical features to serious neurological and neuropsychiatric complication if left untreated. With 
an aging population, screening for vitamin B12 level as part of anemia and cognitive impairment 
workup is more common. More cases are diagnosed, resulting in rising incidence of patients with 
vitamin B12 deficiency. The common causes of vitamin B deficiency are food-cobalamin (vitamin 
B12) malabsorption and pernicious anemia.
Pernicious anemia is an autoimmune gastritis resulting from the destruction of gastric parietal 
cells and consequent impairment of intrinsic factors secretion to bind the ingested vitamin B12. 
Other autoimmune disorders, especially thyroid disease, diabetes mellitus, and vitiligo, are also 
commonly associated with pernicious anemia. The cost and availability of auto-antibodies testing, 
such as intrinsic factor and anti-parietal cell antibodies, can be a barrier to further investigation for 
vitamin B12 deficiency to exclude pernicious anemia. Therefore, the exact prevalence of pernicious 
anemia is difficult to ascertain. It has been estimated that the prevalence of pernicious anemia in 
European countries is approximately 4% of the population (2). It is also well acknowledged that the 
prevalence increase with age and therefore more common in the elderly.
Abbreviation:  RCT, randomized controlled trial.
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For patients with pernicious anemia, lifelong vitamin B12 
therapy is indicated. Vitamin B12 is absorbed in the terminal 
ileum. This absorption is almost entirely dependent on intrinsic 
factor binding to vitamin B12. This bound complex in turn binds 
to the cubam receptor in the terminal ileum and is internalized. 
The complex is eventually released from lysosomes and trans-
ported across the cell membrane bound to transcobalamin in 
the blood circulation. Traditionally, vitamin B12 replacement is 
administered intramuscularly. However, it is believed that oral 
vitamin B12 can be absorbed passively independent of intrinsic 
factors. Passive diffusion accounts for about 1% of total absorp-
tion, and this route of absorption is unaffected in patients with 
pernicious anemia (3).
There were studies in the 1950s and the1960s that showed 
that oral vitamin B12 could be absorbed by patients with perni-
cious anemia and could lead to resolution of the anemia (3–6). 
However, lifelong intramuscular (IM) injection for replacement 
is still a common practice. In 1991, a survey done on Minneapolis 
internists led one commentary to conclude that oral vitamin B12 
replacement for pernicious anemia was one of “medicine’s best 
kept secret” (7). In 1996, when the survey was repeated again 
in the same area, awareness and use of oral vitamin B12 for 
pernicious anemia had increased substantially (0–19%), but the 
majority of doctors still remain unaware of this treatment option 
(61%) (8).
The objective of our review is to inform clinicians on the effec-
tiveness of oral vitamin B12 as adequate replacement in patients 
with pernicious anemia, as well as make recommendations on 
the dosing and frequency of clinical and laboratory monitoring.
MeTHODS
A PubMed search was conducted in April 2016 to identify suit-
able articles published from January 1, 1980 to March 31, 2016. 
The following search strategy was applied: “Administration, Oral” 
(MeSH term) AND “Vitamin B12” (MeSH term) AND “Anaemia, 
Pernicious” (MeSH term). Only studies evaluating the effective-
ness of oral vitamin B12 replacement on pernicious anemia 
patients in entirety or as a subset were included for review. The 
search was limited to English articles.
The search strategy was summarized in the following flow chart.
Flowchart on Selection of Articles
Grading of level of evidence and strength of recommendation 
was based on strength of recommendation taxonomy (SORT) 
framework (9). The description and level of evidence of included 
studies are shown in Table 1.
ReSULTS
Sixty articles were identified through the electronic database 
search. Non-English studies were excluded. The abstracts of 
the remaining 49 articles were evaluated for relevance. Articles 
that did not involve or discuss about patients with perni-
cious  anemia treated with oral vitamin B12 replacement were 
excluded. Duplicated articles and commentary/author’s reply 
were excluded. Another two articles were identified from hand 
search of bibliographic references of the shortlisted articles. 
A total of 12 articles [2 randomized controlled trials (RCTs) 
(10,  11), 3 prospective studies (12–14), 1 systematic review 
(15), and 6 clinical reviews (2, 16–20)] were obtained for the 
review.
effectiveness of Oral vitamin B12
The data given in the studies all supported the use of oral vitamin 
B12 as a valid and effective way of treating vitamin B12 deficiency, 
including pernicious anemia. The age range of the study popula-
tion was 23–92 years old. The RCT by Kuzminski et al. (10) and 
prospective study by Delpre et  al. (12) were done in America. 
The RCT by Bolaman et al. (11) was done in Turkey. The other 
two prospective studies by Nyholm et al. (13) and Andres et al. 
(14) were done in United Kingdom and France, respectively. The 
studies were conducted during the period of late 1990s to early 
2000s.
In Kuzminski’s study, serum vitamin B12 levels were signifi-
cantly higher in the oral (vitamin B12 2000 μg) compared with 
IM (vitamin B12 1000 μg) group (643 ± 328 vs. 306 ± 118 pg/
mL; p < 0.001) at 2 months. The difference was even greater at 
4 months (1005 ± 595 vs. 325 ± 165 pg/mL). Five of the patients 
who had pernicious anemia in the oral vitamin B12 replace-
ment group all had increase in serum vitamin B12 level. Four of 
the 18 in the oral group and 4 of the 15 in the IM group had a 
neurological response with a marked improvement or clearing of 
paresthesia, ataxia, or memory loss.
For Bolaman’s study, there was also an increase in serum 
vitamin B12 levels in both groups (oral vitamin B12 1000 μg vs. 
IM vitamin B12 1000 μg) at 90 days (Oral group 213.8 pg/mL 
and IM group 225.5 pg/mL). There was a statistically significant 
difference between days 0 and 90 in both groups (p < 0.0001), 
but authors did not analyze difference between both groups. Both 
groups reported improvements of cognitive functions, sensory 
neuropathy, and vibration sense, but there was no statistical 
significant difference between both groups.
The systematic review by Butler et al. (15) done on these two 
RCTs concluded that high oral doses of vitamin B12 could be as 
effective as IM administration in achieving short-term hemato-
logical and neurological responses. However, the two RCTs were 
limited by their small sample size and short follow-up period.
The rest of studies also had small sample size but some had 
longer follow-up period (up to 18  months). Normalization of 
serum vitamin B12 levels was seen in all patients (inclusive of 
patients with pernicious anemia) in Delpre’s study. An increase 
TABLe 1 | Description and level of evidence for articles reviewed.
Study and study 
type
Participants, sample 
size, follow-up duration
intervention, outcome measure Results Level of 
evidence 
(based on 
SORT)
Kuzminski et al. 
(10), randomized 
controlled trial 
(RCT), not blinded
Newly diagnosed vitamin 
B12-deficient patients
Oral vitamin B12 2000 μg daily for 120 days 
vs. intramuscular (IM) vitamin B12 1000 μg on 
days 1, 3, 7, 10, 14, 21, 30, 60, and 90
Serum vitamin B12 levels were significantly higher 
in the oral compared with IM group (643 ± 328 vs. 
306 ± 118 pg/mL; p < 0.001) at 2 months. The 
difference was even greater at 4 months (1005 ± 595 
vs. 325 ± 165 pg/mL)
2
N (total number) = 33 Primary outcomes: serum vitamin B12, 
methylmalonic acid, homocysteine neurologic 
responses
Four of the 18 in the oral group and 4 of the 15 in the 
IM group had a neurological response with a marked 
improvement or clearing of paresthesia, ataxia, or 
memory loss
Intervention = 18 (5 had 
pernicious anemia)
Control = 15 (2 had 
pernicious anemia)
120 days
Bolaman et al. 
(11), RCT, not 
blinded
Megaloblastic anemia due 
to vitamin B12 deficiency
Oral vitamin B12 1000 μg daily for 90 days 
vs. IM vitamin B12 1000 μg daily for 10 days, 
then once weekly for 28 days and after that 
continued with once monthly
Serum vitamin B12 levels increased in both groups 
at 90 days (oral group 213.8 pg/mL and IM group 
225.5 pg/mL). There was a statistically significant 
difference between day 0 and day 90 in both groups 
(p < 0.0001) but authors did not analyze difference 
between both groups
2
N = 60 Primary outcomes: serum vitamin B12, 
hemoglobin, platelet count, MCV, WBC, 
mini-mental state examination, neurological 
assessment
Both groups reported improvements of cognitive 
functions, sensory neuropathy, and vibration sense, 
but there was no statistical significant difference 
between both groups
Intervention = 26 (8 had 
presence of anti-parietal 
call antibody)
Control = 34 (3 had 
presence of anti-parietal 
call antibody)
90 days
Delpre et al. (12), 
Prospective, 
open-label
Vitamin B12 deficiency Sublingual vitamin B12 1000 μg daily for 
7–12 days
Normalization of serum vitamin B12 levels was seen 
in all patients. An increase in vitamin B12 level was 
as much as fourfold compared with pretreatment in 
most patients. The mean change of 387.7 pg/mL 
was statistically significant (p = 0.0001, Student’s 
t-test)
3
N = 18 (inclusive of 
patients with pernicious 
anemia but did not state 
number)
Primary outcome: serum vitamin B12
7–12 days
Nyholm et al. (13), 
Prospective, case 
series
Vitamin B12 deficiency Loading dose of IM vitamin B12 till vitamin 
B12 level reached lower 25th centile (418 pg/
mL) and then converted to oral vitamin B12 
1000 μg daily
Oral vitamin B12 was effective in all the patients (no 
patients had to restart IM vitamin B12). At 3 months, 
the median serum vitamin B12 level was 1193 pg/mL
3
N = 40 (10 patients had 
pernicious anemia)
Primary outcomes: serum vitamin B12, 
hemoglobin, MCV, homocysteine, and 
neurological assessment
Oral treatment did not result in any new neurological 
complications
3–18 months
Andres et al. 
(14), Prospective, 
open-label
Pernicious anemia Oral vitamin B12 1000 μg daily for 3 months After 3 months, serum vitamin B12 levels were 
increased in all 9 patients (mean increase, 117.4 pg/
mL; p < 0.001). One patient’s result was not available 
due to technical problem
3
N = 10 Primary outcome: serum vitamin B12, 
secondary outcomes: hemoglobin, platelet 
count, and MCV
3 months
3
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in vitamin B12 level was as much as fourfold compared with 
pretreatment in most patients. The mean change of 387.7  pg/
mL was significant (p = 0.0001 in Student’s t-test). Oral vitamin 
B12 was effective in all the patients (10 patients had pernicious 
anemia) in Nyholm’s study with the median serum vitamin B12 
level of 1193  pg/mL after 3  months of treatment. It was also 
reported that using oral treatment did not result in any new neu-
rological complications. Andres’s study was the only study done 
on patients with pernicious anemia in entirety. All nine patients’ 
serum vitamin B12 levels improved (mean increase, 117.4 pg/mL; 
p < 0.001) after 3 months.
Dosage of Oral vitamin B12  
Replacement Required
In all the five studies, an oral (Delpre’s study via sublingual route) 
dose of 1000  μg vitamin B12 was used with the exception of 
Kuzminski’s study, whereby a higher dose of 2000 μg was used. It 
had been showed that oral vitamin B12 at 1000 μg was adequate 
replacement in pernicious anemia patients.
There was a dose-finding trial done by Eussen et al. (21), and 
the results indicated that the lowest dose of oral vitamin B12 
required to normalize biochemical markers of mild vitamin 
B12 deficiency in older people was more than 200 times greater 
TABLe 2 | SORT recommendations for clinical practice.
Clinical recommendation Strength of 
recommendation
Oral vitamin B12 can be used for adequate replacement in 
patients with pernicious anemia
B
An oral vitamin B12 dose at 1000 μg is adequate 
replacement in patients with pernicious anemia
B
Close monitoring monthly is necessary at the start of 
oral replacement to verify normalization of lab results and 
monitoring for symptoms
C
Thereafter, annual monitoring should suffice
Elevated serum homocysteine and methylmalonic acid 
levels should be included in future assessments of 
pernicious anemia and corrected to normal levels in 
patients with pernicious anemia
C
4
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than the recommended dietary allowance for vitamin B12 of 
approximately 3 μg/day. However, this study did not distinguish 
the extent to which differences in individual responses were due 
to active as opposed to passive absorption of vitamin B12.
In some of the clinical reviews, it was stated that many do 
not use oral vitamin B12 replacement in view of concern on the 
unpredictable absorption at low doses of oral replacement. Daily 
vitamin B12 turnover rate is about 2 μg/day, so an oral dose of 
100–250  μg/day is sufficient for normal patients. However, in 
view of the estimated 1% of total absorption via passive diffu-
sion in patients with pernicious anemia, a 1000 μg daily dose is 
recommended.
Frequency of Monitoring
The outcome measurement of vitamin B12 level was done from 
a range of 1–3 months (exception of Delpre’s study, which was 
done ranging from 9 to 14 days). Improvement in vitamin B12 
was seen as early as within a month. Only in Nyholm’s study, 11 
of their patients were followed up until 18 months, whereby the 
vitamin B12 levels were maintained.
Close monitoring monthly is necessary at the start of oral 
replacement to verify normalization of lab results and monitoring 
for symptoms. Thereafter, annual monitoring should suffice. It 
should be carried out on a regular interval that is safe for patients 
and acceptable to both patients and doctors.
DiSCUSSiON
We summarized the level of evidence of using oral vitamin B12 
replacement for patients with pernicious anemia (Table 1). The 
strength of clinical recommendations based on the SORT frame-
work is provided in Table 2.
There is no “gold standard” in testing for vitamin B12 defi-
ciency. It has been recommended that serum total homocysteine 
(Hcy) and methylmalonic acid (MMA) levels are more sensitive 
indicators of vitamin B12 status in pernicious anemia patients 
without any other disorders of vitamin B12 metabolism. In our 
review, some (10, 13), but not all, studies determine metabolite 
levels (Hcy and MMA) in pernicious anemia to assess effective-
ness of therapy with vitamin B12. Most patients with pernicious 
anemia are not screened genetically for confirmatory causes of 
the disease. There are genetic errors of metabolism where serum 
vitamin B12 levels are normal, but there is a functional (cellular) 
level deficiency of the micronutrient that is often overlooked 
unless Hcy and MMA levels are also measured. Both Hcy and 
MMA levels are elevated in patients with vitamin B12 deficiency. 
Elevated serum Hcy and MMA levels (>3 SDs above the mean in 
normal subjects) have a sensitivity of 95.9 and 98.4%, respectively, 
to diagnose vitamin B12 deficiency (22). The levels decrease 
immediately after treatment and repeat measurements have 
clinical utility to document adequate vitamin B12 replacement. 
However, considerations of using Hcy and MMA levels would 
include cost, availability of the test, as well as having standardized 
reference intervals.
Patients with vitamin B12 deficiency who are symptomatic 
have severe neurological deficits or have critically low blood 
levels of vitamin B12 should be treated with IM administration. 
This is to ensure rapid replenishment of body stores to prevent 
irreversible consequences of deficiency. Subsequently, patients 
may be able to convert to oral replacement with close monitoring. 
For long-term maintenance therapy, oral vitamin B12 replace-
ment can be effective in patients with pernicious anemia. Patient 
preference should be taken into consideration in the choice of 
treatment options. Few studies had included surveying patients 
regarding preference of choice between oral vs. IM replacement 
of vitamin B12. In Delpre’s study, 87% of them preferred tablets 
to injection (12). Eighty-seven percent found the tablets highly 
acceptable, while the remaining 13% agreed that tablets were 
acceptable. It must also be considered that adherence is likely to 
be better if the patient’s preferred route of administration is taken 
into consideration.
Additional factors to consider when helping patient to make 
an informed choice are as follows.
Cost
In a study done in United Kingdom by Vidal-Alaball et al. (23), 
using oral vitamin B12 after diagnosis or switching from IM route 
could save resources in the medium and long term. The use of oral 
route results in significant reduction in manpower costs.
Reduction of Scheduled visits to Clinics
Many patients with vitamin B12 deficiency are elderly and have 
multiple co-morbidities. They often have multiple appointments 
to attend various clinics and may have frequent hospitalization 
episodes. The need to schedule vitamin B12 injections is an avoid-
able addition to the cost and complexity of their care.
Adherence
In patients with non-compliance to oral medication, IM route 
may be a better option to ensure timely administration. On the 
other hand, oral replacement may improve adherence for patients 
who prefer oral medication to injections.
Discomfort/Pain
Oral replacement will be useful in patients who are averse to 
injection. For elderly patients with sarcopenia, injections can 
painful and difficult to administer.
5Chan et al. Oral B12 Pernicious Anemia
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Risk Associated with iM injection
In patients, whereby IM injections are contraindicated because 
of coagulopathy or the use anti-coagulation/anti-platelet medica-
tion. Oral replacement is the best option.
LiMiTATiONS
 1. The review was conducted only using PubMed and hand 
search.
 2. Studies were mainly on patients with vitamin B12 deficiency 
with a subset of patients with pernicious anemia. Therefore, 
the actual sample size of pernicious anemia patients in each 
study may not reach statistical significance. We overcome this 
by triangulating our conclusions and recommendations based 
on the findings from multiple studies and the consistent oral 
vitamin B12 dosage of 1000 μg.
 3. Many of the studies had small sample size and assessed only 
short-term outcomes. The long-term efficacy and side effects 
require further evaluation.
 4. A few possible relevant articles were excluded due to language 
issues.
DiReCTiON OF FUTURe ReSeARCH
A multicenter randomized clinical trial is current in progress in 
Spain primary health-care setting called Project OB12 (24). This 
study aims to provide a more conclusive answer with a large sam-
ple size of 320 patients and longer follow-up period of 52 weeks. 
Further studies should include testing the efficacy of different 
dosages. It may be important to study the knowledge and practices 
of doctors/health-care workers with regard to oral replacement 
therapy with vitamin B12 for patients with pernicious anemia. 
Surveys on patients’ preferences for oral or IM replacement 
would be informative to guide clinical decision-making.
CONCLUSiON
Oral vitamin B12 replacement at 1000 μg daily is an adequate 
alternative to IM B12 injections. Close monitoring with clinical 
review and repeat vitamin B12 levels are required on a monthly 
basis to review symptoms and ensure normalization of B12 defi-
ciency. Elevated serum Hcy and MMA levels should be included 
in future assessments of pernicious anemia and corrected with 
normal levels in patients with pernicious anemia.
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